Myelopeptides and their therapeutic use — US6469137B1
Authors not yet confirmed · 2002 · Primary source linked above
What does this source report?
MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.
- Population and setting
- Cell assays and mouse experiments
- Evidence type
- Patent / reported experiments
- Preparation
- See the original report; formulation details require verification.
- Source language
- See source; English abstract or translated patent text where available
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Patent efficacy proposals are not clinical evidence.
- Commercial product names require formulation-specific confirmation.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected text reviewed
Source access and review scope
Selected original-source text checked; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Author unconfirmed. Myelopeptides and their therapeutic use — US6469137B1 Primary source linked above 2002.
Molekul research summary: https://molekul.io/research/rp-myelopeptide-patent. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry